This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia (WM2)

This study has been completed.
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris Identifier:
First received: October 16, 2008
Last updated: January 17, 2013
Last verified: October 2008
This trial is designed to evaluate the efficacy and toxicity of Bortezomib , an inhibitor of proteasome used in multiple myeloma, in patients with advanced Waldenström's Macroglobulinemia disease.

Condition Intervention Phase
Waldenstrom Macroglobulinemia Drug: BORTEZOMIB Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia

Resource links provided by NLM:

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Complete and partial remission, defined by the 2nd Workshop on Waldenstrom's macroglobulinemia [ Time Frame: 3 months and 6 months ]

Secondary Outcome Measures:
  • Duration of the response [ Time Frame: during the study ]
  • Overall survival [ Time Frame: during the study ]
  • Quality of life [ Time Frame: months 0, 3, 12, 24 ]

Enrollment: 34
Study Start Date: October 2008
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bortezomib
  • Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).
  • For responding patients : up to 6 cycles
  • For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days

Detailed Description:

Open, prospective, multicenter, non controlled phase IIA trial

Primary objectives Evaluation of the efficacy and safety of Velcade in monotherapy for patients with advanced stage Waldenström Macroglobulinemia.

Secondary objectives Evaluation of the activity of the association of High Dose Dexamethasone (HD DXM) with Velcade for patients resistant to Velcade Alone For all patients

  • Overall survival
  • Safety
  • Quality of life
  • Duration of response

sample size: With type I error alpha of 5% and type II error beta of 20% and a two-sided test, the number of patients needed in this study is 34 Number of centers: 28 Centers participating to the French cooperative group CLL/WM


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

● Established diagnosis of Waldenström macroglobulinemia (the 2nd Workshop on Waldenstrom's macroglobulinemia)

Patient must have had 1 (or 2) lines of chemotherapy containing alkylating agent and/or Fludarabine :and /or monoclonal antibody and must have :

  • Life expectancy > 3 months
  • Age > 18 years
  • ECOG performance status 0-1-2
  • ANC > 1 x 109/L
  • Creatinine clearance, calculated according to the formula of cockcroft and Gault > 40 ml/min
  • Total bilirubin < 2x ULN
  • ASAT, ALAT < 2x ULN
  • A negative serum pregnancy test one week prior to treatment must be available both for pre-menopausal women and for women who are < 2 years after the onset of menopause
  • Adequate contraceptive methods for males and pre-menopausal females for 6 months after treatment discontinuation.
  • Written informed consent
  • Platelets> 100X 109

Exclusion Criteria:

  • Active secondary malignancy or chemotherapy/radiotherapy for any neoplastic disease other than Waldenström macroglobulinemia prior to the study
  • Medical condition requiring the long-term (estimated to be more than one month) use of oral corticosteroids
  • Patients with active bacterial, viral or fungal infection
  • Known infection with HIV, Hepatitis B (except post vaccinal profile) or C
  • Treatment with any, other investigational agent or participating in another trial within 30 days prior to entering this study
  • Lactation/pregnancy
  • Concurrent severe diseases which exclude the administration of therapy heart insufficiency NYHA grade III/IV, LEVF < 50% and or RF < 30%, myocardial infarction within the past 6 months prior to study
  • Severe pulmonary or heart problems (acute diffuse pulmonary and pericardial disease)
  • Severe chronic obstructive lung disease with hypoxemia
  • Severe diabetes mellitus
  • Hypertension difficult to control
  • Impaired renal function with creatinine clearance < 40 ml/min according to the formula of Cockcroft and Gault
  • Cerebral dysfunction
  • Richter's syndrome
  • Neuropathy> grade 1
  • Positive Beta HCG
  • Severe Hepato cellular alteration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00777738

Hopital La Pitie Salpetriere
Paris, France, 75013
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Principal Investigator: Véronique LEBLOND, MD, PhD Assistance Publique - Hôpitaux de Paris
  More Information

Responsible Party: Assistance Publique - Hôpitaux de Paris Identifier: NCT00777738     History of Changes
Other Study ID Numbers: P060207
Study First Received: October 16, 2008
Last Updated: January 17, 2013

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Advanced Waldenström's macroglobulinemia

Additional relevant MeSH terms:
Waldenstrom Macroglobulinemia
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents processed this record on August 18, 2017